Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Osteoimmunology

Wnt antagonists: for better or worse?

Molecules involved in developmental signaling pathways have emerged as therapeutic targets for various rheumatic diseases. New research sheds light on the consequences of interfering with these processes.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Manipulating signaling pathways influences ankylosis in mice.

References

  1. Uderhardt, S. et al. Blockade of Dickkopf-1 induces fusion of sacroiliac joints. Ann. Rheum. Dis. doi: 10.1136/ard.2008.102046.

  2. Kansara, M. et al. Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. J. Clin. Invest. 119, 837–851 (2009).

    Article  CAS  Google Scholar 

  3. van der Heijde, D. et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum. 58, 1324–1331 (2008).

    Article  CAS  Google Scholar 

  4. Lories, R. J. U., Derese, I. & Luyten, F. P. Modulation of bone morphogenetic protein signaling inhibits the onset and progression of ankylosing enthesitis. J. Clin. Invest. 115, 1571–1579 (2005).

    Article  CAS  Google Scholar 

  5. Diarra, D. et al. Dickkopf-1 is a master regulator of joint remodeling. Nat. Med. 13, 156–163 (2007).

    Article  CAS  Google Scholar 

  6. Park, M. C., Chung, S. J., Park, Y. B. & Lee, S. K. Suppression of bone morphogenetic proteins attenuates syndesmophytosis by down-regulating Smad pathway in aggrecan-induced spondylitis mice [abstract #484]. Arthritis Rheum. 58 (Suppl.), S346 (2008).

  7. Schett, G., Zwerina, J. & David, J. P. The role of Wnt proteins in arthritis. Nat. Clin. Pract. Rheumatol. 4, 473–480 (2008).

    Article  CAS  Google Scholar 

  8. Luyten, F. P., Tylzanowski, P. & Lories, R. J. Wnt signaling and osteoarthritis. Bone 44, 522–527 (2009).

    Article  CAS  Google Scholar 

  9. Canalis, E., Giustina, A. & Bilezikian, J. P. Mechanisms of anabolic therapies for osteoporosis. N. Engl J. Med. 357, 905–916 (2007).

    Article  CAS  Google Scholar 

  10. Luyten, F. P., Lories, R. J., Verschueren, P., De Vlam, K. & Westhovens, R. Contemporary concepts of inflammation, damage and repair in rheumatic diseases. Best Pract. Res. Clin. Rheumatol. 20, 829–848 (2006).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Frank P. Luyten.

Ethics declarations

Competing interests

R. J. Lories and F. P. Luyten have acted as patent holders on behalf of Katholieke Universiteit Leuven for the use of noggin in the treatment of spondyloarthritis.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lories, R., Luyten, F. Wnt antagonists: for better or worse?. Nat Rev Rheumatol 5, 420–421 (2009). https://doi.org/10.1038/nrrheum.2009.144

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrrheum.2009.144

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing